JP2007502287A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502287A5
JP2007502287A5 JP2006523335A JP2006523335A JP2007502287A5 JP 2007502287 A5 JP2007502287 A5 JP 2007502287A5 JP 2006523335 A JP2006523335 A JP 2006523335A JP 2006523335 A JP2006523335 A JP 2006523335A JP 2007502287 A5 JP2007502287 A5 JP 2007502287A5
Authority
JP
Japan
Prior art keywords
therapeutic
prophylactic agent
tautomer
prodrug
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006523335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502287A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/026021 external-priority patent/WO2005019167A2/en
Publication of JP2007502287A publication Critical patent/JP2007502287A/ja
Publication of JP2007502287A5 publication Critical patent/JP2007502287A5/ja
Withdrawn legal-status Critical Current

Links

JP2006523335A 2003-08-13 2004-08-11 メラニン凝集ホルモン受容体アンタゴニスト Withdrawn JP2007502287A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49473503P 2003-08-13 2003-08-13
PCT/US2004/026021 WO2005019167A2 (en) 2003-08-13 2004-08-11 Melanin concentrating hormone receptor antagonist

Publications (2)

Publication Number Publication Date
JP2007502287A JP2007502287A (ja) 2007-02-08
JP2007502287A5 true JP2007502287A5 (enExample) 2007-06-28

Family

ID=34215897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006523335A Withdrawn JP2007502287A (ja) 2003-08-13 2004-08-11 メラニン凝集ホルモン受容体アンタゴニスト

Country Status (7)

Country Link
US (2) US7514438B2 (enExample)
EP (1) EP1653960A4 (enExample)
JP (1) JP2007502287A (enExample)
AU (1) AU2004266233A1 (enExample)
CA (1) CA2533112A1 (enExample)
MX (1) MXPA06001636A (enExample)
WO (1) WO2005019167A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
UA94412C2 (en) 2005-07-11 2011-05-10 Уайет Glutamate aggrecanase inhibitors
AR055424A1 (es) * 2005-09-12 2007-08-22 Wyeth Corp Formulacion de liberacion sostenida y usos de la misma
GT200600414A (es) * 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
GT200600416A (es) * 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
WO2007039462A2 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Indane derivatives as mch receptor antagonists
AR057451A1 (es) 2005-10-13 2007-12-05 Wyeth Corp Metodos para preparar derivados de acido glutamico
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
AU2007254179B2 (en) 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US20080213252A1 (en) * 2007-01-03 2008-09-04 Ethan Lerner Methods of treating itch
BRPI0806365B8 (pt) 2007-02-06 2021-05-25 Lixte Biotechnology Holdings Inc composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2009045440A1 (en) 2007-10-01 2009-04-09 Lixte Biotechnology Holdings, Inc. Hdac inhibitors
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8058268B2 (en) 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
KR20140052034A (ko) 2011-08-19 2014-05-02 머크 샤프 앤드 돔 코포레이션 신장 외수질 칼륨 채널의 억제제
WO2013039802A1 (en) 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062892A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066717A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2790511B1 (en) 2011-12-16 2016-09-14 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9073864B2 (en) 2012-03-29 2015-07-07 Takeda Pharmaceutical Company Limted Aromatic ring compound
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2968288B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
US9951052B2 (en) 2013-10-31 2018-04-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10426815B2 (en) 2015-01-20 2019-10-01 The General Hospital Corporation Prevention and treatment of itch with an MRGPR antagonist
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2018107004A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
CN119219575B (zh) * 2024-12-03 2025-03-11 天津科技大学 一种抗肿瘤肉桂基哌嗪白藜芦醇偶联物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE276541C (enExample) *
ZA843899B (en) 1983-05-23 1984-12-24 Usv Pharma Corp Compounds for treating hypertension
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
PL321136A1 (en) 1994-11-07 1997-11-24 Pfizer Some substituted derivatives of bencylamine as a new class of specific ligands of neuropeptide y1
EP0918761B1 (en) 1996-07-23 2003-05-02 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
EP0915859B1 (en) 1996-07-23 2003-01-02 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
US5985873A (en) 1996-07-23 1999-11-16 Neurogen Corporation Certain substituted benzylamine derivatives a new class of Neuropeptide-Y1 specific ligands
CN1344321A (zh) 1998-12-28 2002-04-10 武田药品工业株式会社 筛选方法
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
EP1200560A4 (en) 1999-07-14 2003-06-11 Merck & Co Inc MELANINE-CONCENTRATING HORMONE RECEPTOR
WO2001021169A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Mch antagonists
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
GB0001447D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6569861B2 (en) * 2000-07-06 2003-05-27 Neurogen Corporation Melanin concentrating hormone receptor ligands
NZ525723A (en) * 2000-12-22 2004-11-26 Schering Corp 1,4-di-substituted piperidine antagonists for melanin-concentrating hormone (MCH) and their use in the treatment of obesity or diabetes
DE10123958A1 (de) * 2001-05-17 2002-11-28 Aventis Pharma Gmbh Verfahren zur Identifizierung von Liganden für G protein coupled receptors
IL158941A0 (en) 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
US6552188B2 (en) * 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2003073999A2 (en) * 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
AU2003226928A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
US7078430B2 (en) * 2002-07-08 2006-07-18 Ranbaxy Laboratories Limited HMG CoA-reductase inhibitors
FR2842524B1 (fr) * 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
US7091235B2 (en) * 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer

Similar Documents

Publication Publication Date Title
HK1054333A1 (zh) 杂芳基脲神经肽yy5受体拮抗剂
HK1054225A1 (zh) Mch拮抗剂和它们在治疗肥胖中的用途
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
JP2005506370A5 (enExample)
CA2503767A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
JP2007514005A5 (enExample)
WO2006023460A3 (en) COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2005082871A3 (de) Guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
LU92602I2 (fr) Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
MY147442A (en) Imidazoquinolines as lipid kinase inhibitors
CA2472954A1 (en) Aza-arylpiperazines
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
CA2503718A1 (en) Use of serotonin receptor antagonists for the treatment of sleep apnea
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2006066173A3 (en) Novel mch receptor antagonists
JP2008513510A5 (enExample)
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
MX344556B (es) Agonista de subtipo de receptor 5-ht1a.
WO2007039462A3 (en) Indane derivatives as mch receptor antagonists
WO2005040157A3 (en) Novel mch receptor antagonists
JP2007509960A5 (enExample)
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
WO2002036118A3 (en) Heterocyclic derivatives useful as pharmaceutical agents
WO2004026837A3 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses